A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD

Aevi Genomic Medicine, LLC, a Cerecor company1,894 enrolled

Overview

This noninterventional study will assess genomic changes in the metabotropic glutamate receptor (mGluR) network in children and adolescents with ADHD.

Male and female subjects 6 to 17 years of age with a primary psychiatric diagnosis of ADHD will be enrolled in this study. The subject and his or her parent/guardian must agree to genotyping to determine whether the subject has disruptive mutations within any of the approximately 274 mGluR-network genes, and complete an interview that will include information about the subject's ADHD history, treatment, and co-morbidities.

Study Type

OBSERVATIONAL

Enrollment

1,894

Conditions

Attention Deficit Disorder With Hyperactivity

Eligibility

Sex: ALLMin age: 6 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The subject is male or female ≥6 and ≤17 years of age. * The subject has ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition. * The subject, his or her legally responsible representative, and investigator agree to complete ADHD history, treatment, and comorbidity electronic case report form (eCRF). Exclusion Criteria: * The subject or parent/legal guardian is in the opinion of the investigator mentally or legally incapacitated and unable to provide informed consent/assent for participation in the study.

Locations (1)

A.I. DuPont Hospital for Children

Wilmington, Delaware, United States

Outcomes

Primary Outcomes

Presence of mGluR network mutations

Time frame: At study enrollment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.